Healthcare Why Glenmark Pharmaceuticals is on a deal spree Updated : August 17, 2018 01:53 PM IST Glenmark on July 6th announced an exclusive licensing agreement with Australian company Seqirus for one of its drug under development Ryaltris or GSP 301. A month later after the Ryaltris deal, Glenmark announced an exclusive licensing agreement for its oncology molecule under development- GBR 1302. The third deal announced by Glenmark was with its Q1FY19 numbers on 10th of August, just a few days after the agreement on Ryaltris. Subscribe to Moneycontrol PRO at just Rs.33/- per month for the first year. Use code SUPERPRO. Limited period offer. Available on Web and Android.